Normothermic ex-vivo preservation with the portable Organ Care System Lung device for bilateral lung transplantation (INSPIRE): a randomised, open-label, non-inferiority, phase 3 study.
Fiche publication
Date publication
mai 2018
Journal
The Lancet. Respiratory medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr FALCOZ Pierre-Emmanuel, Pr OLLAND Anne
Tous les auteurs :
Warnecke G, Van Raemdonck D, Smith MA, Massard G, Kukreja J, Rea F, Loor G, De Robertis F, Nagendran J, Dhital KK, Moradiellos Díez FJ, Knosalla C, Bermudez CA, Tsui S, McCurry K, Wang IW, Deuse T, Lesèche G, Thomas P, Tudorache I, Kühn C, Avsar M, Wiegmann B, Sommer W, Neyrinck A, Schiavon M, Calebrese F, Santelmo N, Olland A, Falcoz PE, Simon AR, Varela A, Madsen JC, Hertz M, Haverich A, Ardehali A
Lien Pubmed
Résumé
Severe primary graft dysfunction (PGD) of grade 3 (PGD3) is a common serious complication following lung transplantation. We aimed to assess physiological donor lung preservation using the Organ Care System (OCS) Lung device compared with cold static storage.
Mots clés
Adult, Cryopreservation, methods, Female, Humans, Lung Transplantation, adverse effects, Male, Middle Aged, Organ Preservation, instrumentation, Organ Preservation Solutions, Primary Graft Dysfunction, prevention & control, Prospective Studies, Risk Factors, Survival Analysis, Treatment Outcome
Référence
Lancet Respir Med. 2018 05;6(5):357-367